Champions Oncology, Inc. (CSBR) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of Champions Oncology, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSBR
Champions Oncology, Inc.
$4.88HealthcareDelayed quote: Oct 6, 2026, 11:49 AM EDT
PDSB
PDS Biotechnology Corporation
$1.08HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — CSBR vs PDSB
growth of $100 · dividends reinvested · last 10yCSBR +208.7% (+11.9%/yr)PDSB -99.5% (-40.6%/yr)CSBR compounded faster over this window
Log scale — wide-divergence pair
CSBR PDSB
CSBR vs PDSB: by the numbers
- •CSBR is the larger company ($68M vs $60M market cap).
- •Both run net losses; PDSB's is the smaller (0.00% vs -1.87% net margin).
Metrics side by side
Valuation
| Metric | CSBR | PDSB |
|---|---|---|
| Forward P/E | 48.80 | N/A |
| P/S ratio | 1.12 | N/A |
| P/B ratio | 17.42 | N/A |
| EV / EBITDA | 255.71 | N/A |
Profitability
| Metric | CSBR | PDSB |
|---|---|---|
| Gross margin | 49.30% | 0.00% |
| Operating margin | -1.72% | 0.00% |
| Net margin | -1.87% | 0.00% |
| ROE | -29.15% | N/A |
| ROIC | -6.75% | -3699.99% |
Growth (annualized)
| Metric | CSBR | PDSB |
|---|---|---|
| Revenue CAGR (5Y) | 7.25% | N/A |
| Total return CAGR (5Y) | -13.07% | -39.13% |
Frequently asked
- How have CSBR and PDSB total returns compared?
- Over the past 10 years, CSBR delivered 12.07% and PDSB delivered -40.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.